IDH mutations impart a neomorphic enzyme activity that catalyzes the reduction of alpha-ketoglutarate (α-KG) into the suspected oncometabolite 2-hydroxyglutarate (2-HG), resulting in an accumulation of 2-HG in IDH mutant gliomas (6, 7). Here, IDH2 is linked to central nervous system cancer.